RCT | Talazoparib plus enzalutamide prolongs radiographic PFS vs. enzalutamide alone in metastatic castration-resistant prostate cancer

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line Treatment for Patients with mCRPC – ESMO